DE102007002715A1 - Triazolderivat - Google Patents

Triazolderivat Download PDF

Info

Publication number
DE102007002715A1
DE102007002715A1 DE102007002715A DE102007002715A DE102007002715A1 DE 102007002715 A1 DE102007002715 A1 DE 102007002715A1 DE 102007002715 A DE102007002715 A DE 102007002715A DE 102007002715 A DE102007002715 A DE 102007002715A DE 102007002715 A1 DE102007002715 A1 DE 102007002715A1
Authority
DE
Germany
Prior art keywords
carcinoma
diseases
hsp90
vol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102007002715A
Other languages
German (de)
English (en)
Inventor
Hans-Michael Dr. Eggenweiler
Michael Dr. Wolf
Hans-Peter Dr. Buchstaller
Christian Dr. Sirrenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE102007002715A priority Critical patent/DE102007002715A1/de
Priority to PCT/EP2007/010775 priority patent/WO2008086857A1/de
Priority to CN2007800499639A priority patent/CN101583605B/zh
Priority to MYPI20092959 priority patent/MY151452A/en
Priority to US12/523,387 priority patent/US8816070B2/en
Priority to UAA200908637A priority patent/UA98320C2/ru
Priority to JP2009545828A priority patent/JP5266253B2/ja
Priority to BRPI0720956-8A priority patent/BRPI0720956A2/pt
Priority to CA2675737A priority patent/CA2675737C/en
Priority to MX2009007479A priority patent/MX2009007479A/es
Priority to KR1020097016991A priority patent/KR20090101381A/ko
Priority to ES07856537.1T priority patent/ES2455504T3/es
Priority to EP07856537.1A priority patent/EP2102175B1/de
Priority to NZ579069A priority patent/NZ579069A/en
Priority to AU2007344512A priority patent/AU2007344512B2/en
Priority to EA200900913A priority patent/EA015366B1/ru
Priority to CL200800134A priority patent/CL2008000134A1/es
Priority to TW097101845A priority patent/TW200838502A/zh
Priority to PE2008000150A priority patent/PE20090051A1/es
Priority to ARP080100223A priority patent/AR064951A1/es
Publication of DE102007002715A1 publication Critical patent/DE102007002715A1/de
Priority to ZA200905700A priority patent/ZA200905700B/xx
Priority to EC2009009586A priority patent/ECSP099586A/es
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
DE102007002715A 2007-01-18 2007-01-18 Triazolderivat Withdrawn DE102007002715A1 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE102007002715A DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat
EP07856537.1A EP2102175B1 (de) 2007-01-18 2007-12-11 Triazolderivat als hsp 90 inhibitor
ES07856537.1T ES2455504T3 (es) 2007-01-18 2007-12-11 Derivado de triazol como inhibidor de la HSP 90
MYPI20092959 MY151452A (en) 2007-01-18 2007-12-11 Triazole derivative
US12/523,387 US8816070B2 (en) 2007-01-18 2007-12-11 Triazole derivative as an HSP 90 inhibitor
UAA200908637A UA98320C2 (en) 2007-01-18 2007-12-11 Triazol derivative as hsp90 inhibitor
JP2009545828A JP5266253B2 (ja) 2007-01-18 2007-12-11 Ｈｓｐ９０阻害剤としてのトリアゾール誘導体
BRPI0720956-8A BRPI0720956A2 (pt) 2007-01-18 2007-12-11 Derivados de triazol
NZ579069A NZ579069A (en) 2007-01-18 2007-12-11 Triazole derivative as an hsp 90 inhibitor
CN2007800499639A CN101583605B (zh) 2007-01-18 2007-12-11 作为hsp90抑制剂的三唑衍生物
KR1020097016991A KR20090101381A (ko) 2007-01-18 2007-12-11 Ｈｓｐ90 억제제로서의 트리아졸 유도체
PCT/EP2007/010775 WO2008086857A1 (de) 2007-01-18 2007-12-11 Triazolderivat als hsp 90 inhibitor
MX2009007479A MX2009007479A (es) 2007-01-18 2007-12-11 Derivado de triazol.
CA2675737A CA2675737C (en) 2007-01-18 2007-12-11 Triazole derivative
AU2007344512A AU2007344512B2 (en) 2007-01-18 2007-12-11 Triazole derivative as an HSP 90 inhibitor
EA200900913A EA015366B1 (ru) 2007-01-18 2007-12-11 Производное триазола в качестве ингибитора hsp90
CL200800134A CL2008000134A1 (es) 2007-01-18 2008-01-16 Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed
TW097101845A TW200838502A (en) 2007-01-18 2008-01-17 Triazole derivative
PE2008000150A PE20090051A1 (es) 2007-01-18 2008-01-17 Derivados de triazol
ARP080100223A AR064951A1 (es) 2007-01-18 2008-01-18 Derivado de triazol
ZA200905700A ZA200905700B (en) 2007-01-18 2009-08-17 Triazole derivative as an HSP 90 inhibitor
EC2009009586A ECSP099586A (es) 2007-01-18 2009-08-17 Derivado de triazol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007002715A DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat

Publications (1)

Publication Number Publication Date
DE102007002715A1 true DE102007002715A1 (de) 2008-07-24

Family

ID=39345628

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102007002715A Withdrawn DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat

Country Status (22)

Country Link
US (1) US8816070B2 (https=)
EP (1) EP2102175B1 (https=)
JP (1) JP5266253B2 (https=)
KR (1) KR20090101381A (https=)
CN (1) CN101583605B (https=)
AR (1) AR064951A1 (https=)
AU (1) AU2007344512B2 (https=)
BR (1) BRPI0720956A2 (https=)
CA (1) CA2675737C (https=)
CL (1) CL2008000134A1 (https=)
DE (1) DE102007002715A1 (https=)
EA (1) EA015366B1 (https=)
EC (1) ECSP099586A (https=)
ES (1) ES2455504T3 (https=)
MX (1) MX2009007479A (https=)
MY (1) MY151452A (https=)
NZ (1) NZ579069A (https=)
PE (1) PE20090051A1 (https=)
TW (1) TW200838502A (https=)
UA (1) UA98320C2 (https=)
WO (1) WO2008086857A1 (https=)
ZA (1) ZA200905700B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801983B (zh) * 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
BR112012009215A2 (pt) * 2009-10-19 2019-09-24 Synta Pharmaceuticals Corp "terapia combinada contra o cancer com compostos inibidores de hsp90"
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE102010024338A1 (de) 2010-06-18 2011-12-22 Merck Patent Gmbh Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid
MX2013003633A (es) * 2010-10-01 2013-04-24 Taisho Pharmaceutical Co Ltd Derivado de 1, 2, 4-triazolona.
DK2670404T3 (en) * 2011-02-02 2018-11-19 Univ Princeton CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN106478531B (zh) * 2015-08-25 2019-06-28 南京华威医药科技集团有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸中间体
JP7508375B2 (ja) * 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
CN115006395B (zh) * 2022-04-29 2023-03-14 佛山病原微生物研究院 一种xl888在制备用于抗腺病毒感染的药物中的用途

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000053169A2 (en) 1999-03-12 2000-09-14 The United States Of America, Represented By The Secretary Department Of Health And Human Services Method of inhibiting a chaperone protein
US6210974B1 (en) 1997-10-24 2001-04-03 Oregon Health Sciences University Compositions and methods for promoting nerve regeneration
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
WO2002007761A1 (en) 2000-07-20 2002-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
WO2002036075A2 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2004050087A1 (en) 2002-12-05 2004-06-17 Vernalis (Cambridge) Limited 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
WO2004056782A1 (en) 2002-12-19 2004-07-08 Vernalis (Cambridge) Limited Pyrazole compounds
WO2004108080A2 (en) 2003-05-30 2004-12-16 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants
WO2005000213A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
WO2005000211A2 (en) 2003-05-30 2005-01-06 Cosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
WO2005000314A1 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics
WO2005000214A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
WO2005000212A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2005002506A2 (en) 2003-05-30 2005-01-13 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
WO2006087077A2 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Hsp90 hemmende triazolderivate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055760A1 (en) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210974B1 (en) 1997-10-24 2001-04-03 Oregon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000053169A2 (en) 1999-03-12 2000-09-14 The United States Of America, Represented By The Secretary Department Of Health And Human Services Method of inhibiting a chaperone protein
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
WO2002007761A1 (en) 2000-07-20 2002-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
WO2002036075A2 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2004050087A1 (en) 2002-12-05 2004-06-17 Vernalis (Cambridge) Limited 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
WO2004056782A1 (en) 2002-12-19 2004-07-08 Vernalis (Cambridge) Limited Pyrazole compounds
WO2004108080A2 (en) 2003-05-30 2004-12-16 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants
WO2005000213A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
WO2005000211A2 (en) 2003-05-30 2005-01-06 Cosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
WO2005000314A1 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics
WO2005000214A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
WO2005000212A2 (en) 2003-05-30 2005-01-06 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2005002506A2 (en) 2003-05-30 2005-01-13 Kosan Biosciences, Inc. Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
WO2006087077A2 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Hsp90 hemmende triazolderivate

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
A. Kamal et al. beschreiben in Trends in Molecular Medicine, Vol. 10 No. 6 June 2004
Argon Y and Simen BB. 1999 "Grp94, an ER chaperone with protein and peptide binding properties", Semin. Cell Dev. Biol., Vol. 10, pp. 495-505
Bijlmakers M-JJE, Marsh M. 2000 "Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Srckinase p56lck", Mol. Biol. Cell, Vol. 11(5), pp. 1585-1595
Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000 "Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo", Brit. J. Pharmacol., Vol 131(1), pp. 13-16
Carreras CW, Schirmer A, Zhong Z, Santi VS. 2003 "Filter binding assay for the geldanamycin-heat shock protein 90 interaction", Analytical Biochem., Vol 317, pp 40-46
Chef C-F, Chef Y, Dai KD, Chef P-L, Riley DJ and Lee W-H. 1996 "A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock", Mol. Cell. Biol., Vol. 16, pp. 4691-4699
Chen et al., 1996
Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N 2002 "Development of a purine-scaffold novel class of HSP90 binders that inhibit the proliferation of cancer cells and induce the degradation of her2 tyrosine kinase". Bioorganic Med. Chem., Vol 10, pp 3555-3564
Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lozenzino L and Rosen N. 2001 "A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells", Chem. Biol., Vol. 8, pp. 289-299
Conroy SE and Latchman DS. 1996 "Do heat shock proteins have a role in breast cancer?", Brit. J. Cancer, Vol. 74, pp. 717-721
Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB and Toft DO. 2000 "The HSP90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J. Biol. Chem., Vol. 5, pp. 3305-3312
Fuller W, Cuthbert AW. 2000 "Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular Chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate", J. Biol. Chem., Vol. 275(48), pp. 37462-37468
Hickey E, Brandon SE, Smale G, Lloyd D and Weber LA. 1999 "Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein", Mol. Cell. Biol., Vol. 9, pp. 2615-2626
Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron SK, Wu C and Roy-Burman P. 2000 "A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma, Am. J. Pathol., Vol. 156, pp. 857-864
Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA. 2001 "Inhibition of signal transduction by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis", Cancer Res., Vol. 61, pp. 4003-4009
Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee M-0, Park H. 2002 "Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol", Mol. Pharmacol., Vol 62(5), pp. 975-982
Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC and Luqmani YA. 1992 "Clinical
Jolly C and Morimoto RI. 2000 "Role of the heat shock response and molecular chaperones in oncogenesis and cell death", J. Natl. Cancer Inst., Vol. 92, pp. 1564-1572
Kawanishi K, Shiozaki H, Doki V, Sakita I, Inoue M, Yano M, Tsujinata T, Shamma A and Monden M. 1999 "Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus", Cancer, Vol. 85, pp. 1649-1657
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, and Harrap KR. 1993 "Preclinical antitumour evaluation of bis-acetalo-amino-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug", Cancer Research, Vol. 53, pp. 2581-2586
Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P. 1999 "DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90", J. Natl. Cancer Inst., Vol. 91, pp. 1940-1949
Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001 "A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts", Jap. J. Cancer Res., Vol. 92(12), 1342-1351
Kwon HJ, Yoshida M, Abe K, Horinouchi S and Bepple T. 1992 "Radicicol, an agent inducing the reversal of transformed phentoype of src-transformed fibroblasts, Biosci., Biotechnol., Biochem., Vol. 56, pp. 538-539
Lebeau J, Le Cholony C, Prosperi MT and Goubin G. 1991 "Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJE24 Harvey-ras oncogene", Oncogene, Vol. 6, pp. 1125-1132
Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers L. 2000a "The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone", J. Biol. Chem., Vol. 275, pp. 37181-37186
Marcu MG, Schulte TW and Neckers L. 2000b "Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins", J. Natl. Cancer Inst., Vol. 92, pp. 242-248
Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, MacKay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB and Sager R. 2000 "Linking gene expression patterns to therapeutic groups in breast cancer", Cancer Res., Vol. 60, pp. 2232-2238
Neckers L, Schulte TW and Momnaaugh E. 1999 "Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity", Invest. New Drugs, Vol. 17, pp. 361-373
Page J, Heath J, Fulton R, Yalkowsky F, Tabibi E, Tomaszewski J, Smith A and Rodman L. 1997 "Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats", Proc. Am. Assoc. Cancer Res., Vol. 38, pp. 308
Panaretou B, Prodromou C, Roe SM, OBrien R, Ladbury JE, Piper PW and Pearl LH. 1998 "ATP binding and hydrolysis are essential to the function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17, pp. 4829-4836
Pratt WB. 1997 "The role of the HSP90-based chaperone system in signal transduction by nuclear receptors and receptors signalling via MAP kinase", Annu. Rev. Pharmacol. Toxicol., Vol. 37, pp. 297-326
Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, Roe SM, Piper PW and Pearl LH. 2000 "The ATPase cycle of HSP90 drives a molecular "clamp" via transient dimerization of the N-terminal domains", EMBO J., Vol. 19, pp. 4383-4392
Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1997 "Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone", Cell, Vol. 90, pp. 65-75
Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1999 "Structural basis for inhibition of the HSP90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin", J. Med. Chem., Vol. 42, pp. 260-266
Rutherford SL and Lindquist S. 1998 "HSP90 as a capacitor for morphological evolution. Nature, Vol. 396, pp. 336-342
Schulte TW and Neckers LM. 1998 "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamcyin binds to HSP90 and shares important biologic activities with geldanamycin", Cancer Chemother. Pharmacol., Vol. 42, pp. 273-279
Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma SV. 1999 "Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones", Mol. Endocrinology, Vol. 13, pp. 1435-1448
Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft D and Neckers LM. 1998 "Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamcyin", Cell Stress and Chaperones, Vol. 3, pp. 100-108
Sittler, Hum. Mol. Genet., 10, 1307, 2001
Smith DF, Whitesell L and Katsanis E. 1998 "Molecular chaperones: Biology and prospects for pharmacological intervention", Pharmacological Reviews, Vol. 50, pp. 493-513
Smith DF. 2001 "Chaperones in signal transduction", in: Molecular chaperones in the cell (P Lund, ed.; Oxford University Press, Oxford and NY), pp. 165-178
Song et al., 1995
Stebbins et al., 1997
Supko et al., 1995
Tratzelt et al., Proc. Nat. Acad. Sci., 92, 2944, 1995
Tytell et al., 2001
Uehara et al., 1985
Waxman, 2002
Whitesell et al., 1994
Winklhofer et al., J. Biol. Chem., 276, 45160, 2001
Yorgin, 2000
Young et al., 2001
Zhao et al, 1995

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation

Also Published As

Publication number Publication date
US20100113542A1 (en) 2010-05-06
ES2455504T3 (es) 2014-04-15
ECSP099586A (es) 2009-09-29
JP2010516639A (ja) 2010-05-20
BRPI0720956A2 (pt) 2014-03-18
EP2102175A1 (de) 2009-09-23
TW200838502A (en) 2008-10-01
UA98320C2 (en) 2012-05-10
MY151452A (en) 2014-05-30
PE20090051A1 (es) 2009-01-26
CN101583605A (zh) 2009-11-18
WO2008086857A1 (de) 2008-07-24
AU2007344512B2 (en) 2012-11-01
CA2675737A1 (en) 2008-07-24
CN101583605B (zh) 2013-06-19
US8816070B2 (en) 2014-08-26
JP5266253B2 (ja) 2013-08-21
MX2009007479A (es) 2009-08-13
KR20090101381A (ko) 2009-09-25
AU2007344512A1 (en) 2008-07-24
CL2008000134A1 (es) 2008-05-16
EA015366B1 (ru) 2011-06-30
AR064951A1 (es) 2009-05-06
NZ579069A (en) 2011-09-30
EP2102175B1 (de) 2014-01-22
CA2675737C (en) 2015-03-24
EA200900913A1 (ru) 2009-12-30
ZA200905700B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
EP2155690B1 (de) Indazolamidderivate
EP1853570B1 (de) Hsp90 hemmende triazolderivate
EP2102175B1 (de) Triazolderivat als hsp 90 inhibitor
EP2023922B1 (de) Triazolderivate ii
EP1799649B1 (de) 3-(2-hydroxyphenyl)-pyrazole und ihre verwendung als hsp90 modulatoren
EP2356110B1 (de) Chinazolinamidderivate
EP2181092B1 (de) 1,3-dihydro-isoindolderivate
DE102007032739A1 (de) Chinazolinamidderivate
EP2035391A1 (de) Indazolderivate zur behandlung von hsp90-induzierten krankheiten
DE102005022977A1 (de) Phenylchinazolinderivate
WO2007098835A1 (de) Aminopyrymidinderivate
EP1912994B1 (de) Adeninderivate
EP2504314B1 (de) Chinazolinderivate
DE102005024245A1 (de) Thienopyridine
EP1853609B1 (de) Thienopyridinderivate und ihre verwendung als hsp90 modulatoren

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee